Participants and Setting
cancer, hypersensitivity, androgen-dependent carcinoma, polycythemia
CANCER, HYPERSENSITIVITY, POLYCYTHEMIA
Participants were transgender and gender-diverse individuals aged 18 to 70 years seeking initiation of testosterone therapy with no previous testosterone treatment. Individuals were recruited from endocrinology outpatient clinics and primary care clinics specializing in transgender and gender-diverse health in Melbourne, Australia, from November 1, 2021, to July 22, 2022. Individuals were excluded if they had a contraindication to receipt of testosterone, including androgen-dependent carcinoma, known cancer, hypersensitivity to the active substance or to any of the excipients, polycythemia (defined as hematocrit >50% [to convert to proportion of 1.0, multiply by 0.01]